|Daily Range||$8.40 - $8.63|
|52-Week Range||$6.81 - $13.09|
|Dividend (Yield)||$0.00 (0.0%)|
|Average Daily Volume||827,543|
|Current FY EPS||-$1.69|
Solazyme (SZYM) Description
Solazyme Inc. is in the business of transforming a range of low-cost plant-based sugars into high-value oils. Website: http://www.solazyme.com/
News & Commentary
Solazyme recently announced that it was pushing back the start-up of its commercial scale facility in Brazil, built with partner Bunge, by a few months. The news serves as a reminder that delays are always possible for developmental companies. Are more on the way in 2014?
A stadium collapse in the city of Sao Paulo will put added pressure on Brazil's already stressed construction sector and could lead to an increase in construction costs. What does it mean for companies such as Cosan, Amyris, and Solazyme, which are all planning construction projects in the country?
A new year is upon us and we have 3 bold predictions for the coming year!
The invention of polymerase chain reaction, or PCR, in 1983 may not be directly relevant to everyday investors, but it has gone a long way in spurring innovation in biopharmaceuticals, biotech crops, and industrial biotech. If you own a company in one of those industries, then it's likely that you should pay your respects to PCR.
The Dow hit a new record high, but Tesla Motors and Solazyme each dropped 15%, while VIVUS posted a 12% drop. Find out why these stocks didn't join in the market's bull run today.
Third quarter results are in at Solazyme. Will production delays disrupt the company's ambitious plans going forward?